Chol-POD / siGLO topical eye drop
Sequence: CGGGARKKAAKAARKKAAKAARKKAAKAARKKAAKA
| Experiment Id | EXP001969 |
|---|---|
| Paper | Effective In Vivo Topical Delivery of siRNA and Gene Silencing in Intact Corneal Epithelium Using a |
| Peptide | Chol-POD / siGLO topical eye drop |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | 35:1 (625 µM peptide + 18 µM siRNA; 2.5 µL drop/eye) |
| Formulation Format | CPP–siRNA polyplex (topical ocular delivery) |
| Formulation Components | Chol-POD complexed with siGLO; fluorescence monitored up to 24 h and corneal sections imaged. |
| Size Nm | 150.80 |
| Zeta Mv | 15.60 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Mouse (WT C57BL/6) cornea (fluorescence uptake assay) |
| Administration Route | Topical eye drop to cornea (2.5 µL per eye; maintained horizontal 15 min post-application) |
| Output Type | In vivo uptake/distribution (IVIS fluorescence; corneal cryosections) |
| Output Value | Fluorescence detected in cornea up to 24 h; signal higher than siGLO-only control. Palm-POD shows stronger fluorescence vs Chol-POD; QN-Palm-POD also persists. |
| Output Units | |
| Output Notes | These experiments demonstrate uptake/retention in corneal layers but are not a functional gene-silencing endpoint. |
| Toxicity Notes | No overt corneal inflammation reported for QN-Palm-POD regimen; chloroquine avoided for in vivo toxicity concerns. |
| Curation Notes |